Nearing the end of 2022, the COVID-19 pandemic clearly no longer dominates the clinical activity reported by biopharma companies. Overall clinical data tracked by BioWorld is down significantly, as is the proportion focused on the SARS-Cov-2 virus. Therapeutics and vaccines targeting cancer, infectious diseases and neurological disorders, however, remain a stronghold.
Easy access to financing, talent, and connection to sizable potential markets are Hong Kong’s advantages to develop the health care robotics industry, according to speakers at the Asia Summit on Global Health.
South Korea’s regenerative medicine market is expected to grow from $51 million in 2016 to $320 million by 2026, growing at a compound annual growth rate of 20%, So Ra Park, chair and founder of Korea’s Regenerative Medicine Acceleration Foundation said.
With a 52% increase in patent filings and a 160% jump in research publications, the RNA technology field has exploded in the last 10 to 12 years, and the U.S. and mainland China are paving the way. Identifying seven emerging RNA innovators, Clarivate plc’s RNA Technology Companies to Watch is a new report that harnesses data and insights from both Clarivate and BioWorld.
A strong third quarter has pushed biopharma financings ahead of several pre-pandemic years, as follow-on offerings and private placements picked up the pace. IPOs and venture capital rounds dipped below prior quarters, but the overall amount raised so far this year has placed 2022 as the fifth best financing year among the last 10, ahead of both 2019 and 2017.
Keeping innovation growing at a fast clip while retaining new global supply chain capacity built up during the pandemic were the main topics of discussion at the Bio Asia-Taiwan conference July 27 in Taipei. With the theme of the conference, “Connecting the Asia Value Chain,” Taiwan Vice President Ching-Te Lai said the pandemic has demonstrated Taiwan’s resilience as well as the strength of the global biopharma industry.
Biopharma deals during the second quarter of 2022 fell short of each of the last two years with 379 completed deals valued at $36.9 billion, but the year is still the strongest to date. Thanks to the record-breaking first quarter, deals in the first half of this year are ahead of all other years, reaching a total value of $93.8 billion, 6.5% more than 2020, the next highest first half.
Nonprofit deals with biopharma companies in 2022 indicate that 92% of the disclosed funds are going toward infectious disease therapies, with COVID-19 accounting for 79% of the total.
Although the death toll in the U.S. is nearing 1 million lives lost, signs continue to suggest that an end is in sight for the COVID-19 pandemic, the most disruptive global health crisis in a century.
RSS
